COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

/EIN News/ — LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health company dedicated to accelerating patient access to evidence-based innovation in mental health , announced today management will host a fireside chat at the Jefferies Innovation in Mental Health Summit on September 22, 2022 at 8:30 am ET.

A live audio webcast of the fireside chat will be accessible on the Events page of the Investors section of the COMPASS website. Each replay of the webcast is accessible for 30 days after each event. Visit for more information

About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those with mental health problems who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy using our proprietary formulation of synthetic psilocybin, COMP360, administered in conjunction with psychological support. COMP360 has been designated a breakthrough therapy for treatment-resistant depression (TRD) by the U.S. Food and Drug Administration (FDA), and we have completed a Phase IIb clinical trial of psilocybin therapy for TRD at 22 sites in Europe and North America. This was the largest randomized, controlled, double-blind clinical trial of psilocybin therapy ever conducted, and our top-line data showed a statistically significant (p<0.001) and clinically relevant improvement in the severity of depressive symptoms at three weeks in patients receiving a single high dose of COMP360 psilocybin with psychological support. We are also conducting phase II clinical trials of COMP360 psilocybin therapy in post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco, USA. Our vision is a world of mental well-being.

Also Read :  Callers keep flooding 988 mental health, suicide helpline

Availability of more information on COMPASS Pathways
Investors and others should note that we communicate with our investors and the public through our website (, our investor relations website (, and through social media (LinkedIn), including but not limited to limited to investor presentations and investor briefings, filings with the US Securities and Exchange Commission, press releases, public conference calls and webcasts. The information we publish on these channels and websites could be considered material information. Therefore, we encourage investors, the media and others with an interest in us to regularly review the information published through these channels, including the Investor Relations website. This list of channels may be updated from time to time on our Investor Relations website and may include additional social media channels. Nothing contained on our website or these Channels, or any website accessible from our website or these Channels, is not deemed to be incorporated by reference in any filing under the Securities Act of 1933.

Also Read :  Ellipsis Health and Tiatros Partner to Advance Mental Health and Improve Access to Quality Care

Media: Amy Lawrence, [email protected], +44 7813 777 919
Investors: Stephen Schultz, [email protected], +1.401.290.7324

Primary logo

Source link